Scarica l'app Stockscreener
10.75
6.65%
0.67
Dopo l'orario di chiusura:
10.75
Precedente Chiudi:
$10.08
Aprire:
$10.12
Volume 24 ore:
166.99K
Relative Volume:
0.78
Capitalizzazione di mercato:
$410.86M
Reddito:
$239.40M
Utile/perdita netta:
$104.44M
Rapporto P/E:
3.6318
EPS:
2.96
Flusso di cassa netto:
$-18.50M
1 W Prestazione:
+4.57%
1M Prestazione:
+4.17%
6M Prestazione:
+54.23%
1 anno Prestazione:
-37.68%
Intervallo 1D:
$10.11
$10.88
Intervallo di 1 settimana:
$9.84
$10.88
Portata 52W:
$4.93
$17.15
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Confronta TRDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
10.75 | 385.25M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
Price-Driven Insight from (TRDA) for Rule-Based Strategy - Stock Traders Daily
Vesuvius India Limited Moves Into Overbought Range Analysts CautiousSell Signals and Alerts & Double Or Triple Wealth - bollywoodhelpline.com
Entrada Therapeutics Inc (TRDA) Stock News & Articles - 24/7 Wall St.
AVP Infracon Limited Breaks Below Key Support LevelGlobal Trade Effects & Affordable Trading Strategies - Bollywood Helpline
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Analyst Downgrade: Will Entrada Therapeutics Inc stock return to pre crisis levels2025 Market Overview & Verified Entry Point Detection - moha.gov.vn
Tubes Limited Inches Toward Key Resistance — Will It BreakRisk Adjusted Returns & Low Risk Trading Ideas - Bollywood Helpline
Beeyu Overseas Limited Included in Top Momentum ScanVolume Profile Analysis & Big Data Market Reports - Bollywood Helpline
Option Seller’s Risk Unlimited (in theory)REITs Market Trends & Big Gains Small Capital - bollywoodhelpline.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics Earnings Notes - Trefis
Is Entrada Therapeutics Inc. stock vulnerable to regulatory risksChart Signals & Weekly Momentum Picks - Улправда
How Entrada Therapeutics Inc. stock compares to industry benchmarksDay Trade & Safe Capital Allocation Plans - Улправда
Is Entrada Therapeutics Inc. stock positioned for long term growth2025 Volume Leaders & Fast Momentum Stock Entry Tips - Улправда
Is Entrada Therapeutics Inc. stock safe for conservative investors2025 Big Picture & Verified Trade Idea Suggestions - Улправда
How Entrada Therapeutics Inc. stock reacts to job market dataWeekly Trade Review & Risk Controlled Swing Alerts - Улправда
How resilient is Entrada Therapeutics Inc. stock in market downturnsJuly 2025 Snapshot & Weekly High Return Stock Forecasts - DonanımHaber
What insider trading reveals about Entrada Therapeutics Inc. stockQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Bölüm Sonu Canavarı
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Will Entrada Therapeutics Inc. stock benefit from commodity pricesWeekly Trading Summary & Verified Technical Signals - DonanımHaber
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Entrada Therapeutics : Corporate Presentation December 2025 - marketscreener.com
5AM Venture Management LLC Has $28.95 Million Stake in Entrada Therapeutics, Inc. $TRDA - MarketBeat
Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily
Entrada Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Brokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) Price Target at $20.67 - Defense World
Baker Bros. Advisors LP Increases Stake in Entrada Therapeutics Inc. - GuruFocus
Major Investment Alert: Baker Bros. Advisors Boosts Stake in Entrada Therapeutics! - TipRanks
Kory James Wentworth Sells 8,910 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Insider Sell: Kory Wentworth Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus
Entrada Therapeutics CFO Sells Shares Under Trading Plan - TradingView
CFO Wentworth Sells 8,910 ($88.9K) Of Entrada Therapeutics Inc [TRDA] - TradingView
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
CFO Wentworth Files To Sell 8,910 Of Entrada Therapeutics Inc [TRDA] - TradingView
Will Entrada Therapeutics Inc. stock deliver shareholder valueWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Entrada Therapeutics (TRDA) Price Target Decreased by 10.81% to 16.83 - MSN
Why Entrada Therapeutics Inc. stock is favored by pension fundsTrade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
(TRDA) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Questex’s Fierce Life Sciences Announces 2025 Innovation Awards Winners - GlobeNewswire Inc.
How risky is Entrada Therapeutics Inc. stock now2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells 200,000 Shares of Stock - MarketBeat
Can Entrada Therapeutics Inc. stock resist market sell offs2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Major Stock Sell-Offs at Entrada Therapeutics Inc! - TipRanks
Applying big data sentiment scoring on Entrada Therapeutics Inc.2025 Top Decliners & Consistent Return Investment Signals - newser.com
Owner 5AM Ventures V LP Sells 200,000 ($1.8M) Of Entrada Therapeutics Inc [TRDA] - TradingView
Chmn Parmar Sells 200,000 ($1.8M) Of Entrada Therapeutics Inc [TRDA] - TradingView
Is Entrada Therapeutics Inc a good long term investmentEarnings Growth Projections & Real-Life Case Studies You Can Follow - earlytimes.in
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):